XEVUDY

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Japan, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug XEVUDY contains one active pharmaceutical ingredient (API):

1 Sotrovimab UNII 1MTK0BPN8V - SOTROVIMAB

Sotrovimab is a dual action, engineered human IgG1 mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. It is used for the treatment of symptomatic adults and adolescents with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection. Read about Sotrovimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XEVUDY Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BD	Antiviral monoclonal antibodies	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins
Discover more medicines within J06BD

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1872817
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1211562001
Country: FR	Base de données publique des médicaments	Identifier(s): 62519824
Country: IT	Agenzia del Farmaco	Identifier(s): 049812011
Country: JP	医薬品医療機器総合機構	Identifier(s): 62504A4A1023
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093887
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100463322
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68344001